Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors
To compare oocyte cryopreservation cycles performed in cancer patients to those of infertile women.
Cancer patients referred for fertility preservation underwent counseling in compliance with the ASRM; those electing oocyte cryopreservation were included. Ovarian stimulation was achieved with injectable gonadotropins and freezing was performed using slow-cooling and vitrification methods.
Fifty cancer patients (mean age 31 y) underwent oocyte cryopreservation; adequate ovarian stimulation was achieved in 10 ± 0.3 days. The outcome from these cycles included a mean peak estradiol of 2,376 pg/ml and an average of 19 oocytes retrieved (15 mature oocytes were cryopreserved/cycle). All patients tolerated ovarian hyperstimulation. There were no significant differences noted between cryopreservation cycles performed in cancer patients and in women without malignancy.
Oocyte cryopreservation appears to be a feasible fertility preservation method for reproductive-age women diagnosed with cancer. This modality is not only effective but also, providing a multidiscipline effort, can be completed in timely fashion.
KeywordsCancer survivor Fertility preservation Oocyte cryopreservation Quality-of-life
The authors would like to thank the entire IVF team at the NYUFC for their efforts and participation in the oocyte cryopreservation program and all the oncologists who referred patients for fertility preservation treatment. Dr. Noyes would also like to thank Dr. Eleonora Porcu of Bologna, Italy for introducing her to oocyte cryopreservation technology and its application as a fertility preservation measure in cancer patients.
Schering Plough provided fertility medication for some of the non-cancer patients.
Conflicts of Interest
- 2.Surveillance, Epidemiology and End Results data. http://seer.cancer.gov/statfacts/html/all.html. Accessed March 4, 2009.
- 3.Knopman JM, Papadopoulos E, Grifo J, Fino ME, Noyes N. Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 15 Feb 2010. doi: 10.1016/S1470-2045(09)70317-1, [Epup ahead of print].
- 5.Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Essential elements of informed consent for elective oocyte cryopreservation: a practice committee opinion. Fertil Steril. 2008;90:S134–5.Google Scholar
- 6.Noyes N, Knopman J, Labella P, McCaffrey C, Clark-Williams M, Grifo J. Oocyte cryopreservation outcomes including pre-cryo and post-thaw meiotic spindle evaluation following slow cooling and vitrification of human oocytes. Fertil Steril. 26 Feb 2010. doi: 10.1016/j.fertnstert.2010.01.019, [Epub ahead of print].
- 12.Magelseen H, Brydoy M, Fossa SD. The effects of cancer and cancer treatments on male reproductive function. Nat Clin Pract. 2006;3:312–22.Google Scholar
- 15.Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89:84–91.CrossRefPubMedGoogle Scholar